Hemophilia without prophylaxis: Assessment of joint range of
Por um escritor misterioso
Descrição
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
PDF] Effect of joint range of motion on health-related quality of life in children with hemophilia
PDF) Emicizumab Prophylaxis in Hemophilia A with Inhibitors
The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B - ScienceDirect
Impact of the HEAD-US Scoring System for Observing the Protective Effect of Prophylaxis in Hemophilia Patients: A Prospective, Multicenter, Observational Study
Bleeding In Joints A Common Symptom Of Haemophilia: Preventing Joint Degeneration
Hemophilia Nursing Care Planning and Management Study Guide - Nurseslabs
Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A - Research and Practice in Thrombosis and Haemostasis
Algorithm for management of emergency situations in patients with
Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
Selecting Treatment Approaches in Hemophilia (Transcript)
Resolution of Target Joints (TJs) in Children with Severe Haemophilia A (HA) Treated with Turoctocog Alfa Pegol (N8-GP) Prophylaxis: Results from the Pathfinder 5 Trial - ISTH Congress Abstracts
Full article: Joint status and related risk factors in patients with severe hemophilia A: a single-center cross-sectional study
Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM), Journal of Patient-Reported Outcomes
Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults - Research and Practice in Thrombosis
de
por adulto (o preço varia de acordo com o tamanho do grupo)